Point-of-Care Testing for Women Health Market Overview
The Point-of-Care Testing for Women Health Market was valued at USD 17.69 Billion in 2024. The industry is projected to grow from USD 18.83 Billion in 2025 to USD 33.74 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.26% during the forecast period (2025-2035).
The high prevalence of infectious diseases in women and increasing cases of infertility among women, along with growing strategic initiatives associated with point-of-care testing for women's health, are driving the market's growth.
As per the Analyst at MRFR, the high prevalence of infectious diseases among women is significantly fueling the growth of the global point-of-care (POC) testing market for women’s health. This drives demand for rapid and accessible diagnostic solutions.
Conditions such as sexually transmitted infections (STIs), urinary tract infections (UTIs), and HPV require timely detection for effective treatment and management. POC tests are highly valuable due to their ability to deliver quick results and facilitate early intervention.
For instance, the Cleveland Clinic stated that up to 75% of women or individuals assigned female at birth (AFAB) will experience at least one vaginal yeast infection during their lifetime. More than half will encounter two or more infections.
Yeast infections rank as the second most frequent cause of vaginitis, after bacterial vaginosis, which is the most common.
FIGURE 1: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET VALUE (2019-2035) USD BILLION
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Point-of-Care Testing for Women Health Market Opportunity
RISING AWARENESS AND HEALTH INITIATIVES
Rising awareness and health initiatives related to women's health are significantly fueling the growth of the global point-of-care (POC) testing market for women’s health. Increased public education and advocacy campaigns have heightened awareness of various health issues.
These issues affect women, such as reproductive health, sexually transmitted infections (STIs), and chronic conditions. For instance, consider the Women’s Health Awareness Community Engagement Program.
This mission goal is to carry out research that involves the community, provide education, and advocate for issues related to environmental health disparities, environmental and social justice, health and well-being, and gender and racial inequalities.
All these efforts aim to strengthen community health resilience. Its focus is on working with community partners to develop research, evidence-based solutions, health education, and environmental literacy.
Its efforts are geared towards empowering women to take charge of their health, grasp the crucial links between health and the environment, and actively advocate for environmental justice issues affecting their communities.
The Government of India has introduced a range of schemes and initiatives aimed at improving healthcare accessibility for everyone across the country, including women, rural communities, and those from SC/ST backgrounds.
These schemes and initiatives include Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA) which provides pregnant women a fixed day, free of cost assured and quality antenatal check up by a Specialist/Medical Officer on the 9th day of every month.
These initiatives emphasize the importance of early detection and preventive care, driving demand for convenient and accessible testing solutions. POC tests, which offer rapid results and ease of use, align with these health goals.
They provide timely diagnostics and facilitate proactive management of women’s health. Consequently, the surge in awareness and targeted health programs is accelerating the adoption and expansion of POC testing technologies in the market.
Point-of-Care Testing for Women Health Market Segment Insights
Point-of-Care Testing for Women Health System by Product Insights
Based on Product, this segment includes Instruments/Devices, Reagents & Kits, Consumables. The Reagents & Kits segment dominated the global market in 2024, while the Instruments/Devices segment is projected to be the fastest–growing segment during the forecast period.
Reagents and kits refer to specialized diagnostic tools designed for on-site, rapid testing outside of traditional laboratory settings. Reagents are chemical substances or compounds used in tests to detect, measure, or analyze specific biomarkers related to women's health conditions.
These conditions include pregnancy, hormonal levels, or infectious diseases. Kits encompass a complete set of components, including reagents, testing devices, and instructions, that facilitate the user-friendly and accurate performance of tests.
These reagents and kits are essential for enabling timely and effective health monitoring, empowering both healthcare providers and individuals with the ability to perform tests quickly and conveniently in various settings.
FIGURE 2: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE BY PRODUCT 2024 AND 2035 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Point-of-Care Testing for Women Health System by Age Insights
Based on Age, this segment includes Adolescent, Adult, Geriatric. The Adult segment dominated the global market in 2024, while the Adolescent segment is projected to be the fastest–growing segment during the forecast period.
The increasing prevalence of chronic conditions such as diabetes, cardiovascular diseases, and cancer among adult women is driving demand for timely and accessible diagnostic testing.
For instance, according to womenshealth.gov, in 2022, approximately 1 in 9 adult women in the United States, or 15 million women, have diabetes. Moreover, according to World Health Organization, in 157 out of 185 nations, breast cancer was the most frequent cancer among women in 2022.
The disease is directly responsible for 1.5 million fatalities annually. Additionally, the growing emphasis on personalized and preventive healthcare solutions is enhancing the adoption of POCT, which offers rapid and accurate results.
Point-of-Care Testing for Women Health System by Sample Test Insights
Based on Sample Test, this segment includes Serum, Plasma, Whole Blood, Urine, Others. The Whole Blood segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period.
The use of whole blood as a sample type is driven by several key factors. The convenience and simplicity of whole blood collection streamline the testing process, making it ideal for rapid and efficient diagnostics in diverse settings, from clinics to home environments.
Whole blood tests are versatile, applicable to a broad range of health markers such as glucose levels, cholesterol, and infectious disease indicators, thereby supporting comprehensive women's health monitoring.
The growing emphasis on routine health monitoring and early disease detection, coupled with increasing patient preference for quick and minimally invasive tests, further drives the adoption of whole blood-based POCT solutions.
Point-of-Care Testing for Women Health System by Test Type Insights
Based on Test Type, this segment includes Testosterone Test, Estradiol Test, Anti-Müllerian Hormone Test, Prolactin Test, Progesterone Test, Follicle-stimulating Hormone Test, Luteinizing Hormone Test, β-hCG Test, Others. The β-hCG Test segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period.
β-hCG Test is a diagnostic test that measures the concentration of beta-human chorionic gonadotropin (β-hCG) in the blood or urine. This hormone is an early marker of pregnancy and is used to confirm pregnancy, monitor pregnancy progression, and diagnose certain medical conditions.
β-hCG is produced by the placenta shortly after implantation, making it a reliable marker for detecting pregnancy.
Point-of-Care Testing for Women Health System by Technology Insights
Based on Technology, this segment includes Colloidal Gold Lateral Flow Assays, Fluorescence Immunoassays, Lab-on-a-Chip, Others. The Fluorescence Immunoassays segment dominated the global market in 2024, while the Lab-on-a-Chip segment is projected to be the fastest–growing segment during the forecast period.
Fluorescence Immunoassays are a sophisticated diagnostic technology that leverages the principles of fluorescence to detect and quantify specific biomolecules through antigen-antibody interactions.
This technology is widely used in clinical diagnostics, research, and various applications requiring precise and sensitive detection of target analytes. Fluorescence immunoassays utilize fluorescent labels to provide a visual signal that indicates the presence of a specific target molecule.
The basic principle involves the use of fluorescent dyes or proteins that emit light when excited by a specific wavelength. This fluorescence is detected and measured to determine the quantity of the target analyte in the sample.
Point-of-Care Testing for Women Health System by Application Insights
Based on Application, this segment includes Gestational Diabetes, Vaginal Infection, Urinary Tract Infection, Cervical Cancer or Pre-cancerous Conditions, Hemoglobin Deficiency, Breast Cancer, Thyroid Disease, Sexually Transmitted Infections (Chlamydia, Gonorrhea, HIV, Syphilis, Others), Fertility Conditions (Polycystic Ovary Syndrome, Ovulation Disorders, Others), Pregnancy Testing, Others.
The Pregnancy Testing segment dominated the global market in 2024, while the Fertility Conditions segment is projected to be the fastest–growing segment during the forecast period.
This growth is driven by a rising prevalence of infertility issues, such as polycystic ovary syndrome (PCOS) and ovulation disorders, along with increasing age of first-time pregnancies and growing awareness about reproductive health.
Advances in diagnostic tools and increased access to fertility treatments are further accelerating demand in this segment.
Point-of-Care Testing for Women Health System by Distribution Channel Insights
Based on Distribution Channel, this segment includes Offline (Hospital Pharmacies, Retail Pharmacies, Hypermarket/Supermarket) and Online (E-commerce Platforms and Online Pharmacies).
The Offline segment dominated the global market in 2024, while the Online segment is projected to be the fastest–growing segment during the forecast period.
The established relationships between manufacturers and traditional distribution networks, such as medical device distributors, wholesalers, and specialty suppliers, facilitate streamlined procurement and inventory management.
Offline channels benefit from the tangible presence and direct interaction between sales representatives and healthcare providers, enabling personalized demonstrations, hands-on training, and immediate support.
Point-of-Care Testing for Women Health System by End-User Insights
Based on End-User, this segment includes Hospitals, Diagnostic Laboratories, Home Settings, Others. The Home Settings segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period.
In home settings, Point-of-Care Testing (POCT) for women’s health is gaining traction due to its alignment with the growing demand for accessible and convenient health management solutions.
The adoption of POCT in home environments is driven by the need for immediate, reliable diagnostic tools that empower individuals to monitor their health proactively, without the necessity of frequent clinic visits.
These devices, which include tests for pregnancy, ovulation, and urinary tract infections, provide rapid and accurate results, facilitating timely and informed health decisions.
The ease of use inherent in home POCT devices minimizes the need for specialized training, broadening their appeal and usability across diverse demographics. Additionally, the ability to perform tests at home significantly reduces healthcare costs and alleviates pressure on healthcare systems by diminishing the need for in-person consultations.
Point-of-Care Testing for Women Health System Regional Insights
Based on the Region, the global Point-of-Care Testing for Women Health is segmented into North America, Europe, Asia-Pacific and Rest of the World.
Major demand factors driving the North America market are the high prevalence of infectious diseases in women and increasing cases of infertility among women and growing strategic initiatives associated with the point-of-care testing for women health.
The North America Point-of-Care (POC) Testing for Women's Health market is experiencing significant growth, driven by increasing demand for rapid diagnostic tools, especially for pregnancy, fertility, and sexually transmitted infections.
Advancements in POC technology, including portable and easy-to-use devices, are enhancing accessibility and convenience, making them popular in both clinical and home settings.
In January 2021, Ovry, a Canadian start-up focused on reducing pregnancy-related stress for women, sells extremely thin pregnancy and ovulation test strips in boxes of four or eighteen strips.
In addition, the company offers the product in discreet packaging and at a significantly lower cost than other pregnancy tests on the market.
FIGURE 3: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET VALUE BY REGION 2024 AND 2035 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Further, the countries considered in the scope of the Application Tracking System Market are the US, Canada, Mexico, Germany, France, the UK, Italy, Spain, China, India, Japan, Australia, South Korea, Southeast Asia, Malaysia, Singapore, Thailand, Vietnam, Philippines, Indonesia, Middle East & Africa, South America, Brazil, Argentina, Chile and others.
Global Point-of-Care Testing for Women Health Key Market Players & Competitive Insights
Many global, regional, and local vendors characterize the Point-of-Care Testing for Women Health Market. The market is highly competitive, with all the players competing to gain market share.
Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth.
The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.
The major competitors in the market are Swiss Precision Diagnostics GmbH- Clearblue, Wondfo, Church & Dwight Co., Inc.-First Response, Hangzhou Singclean Medical Products Co., Ltd., W.H.P.M., Inc., SEKISUI Diagnostics, INNOVITA Biological Technology Co., Ltd., Yangzhou VIOMED, Cofoe Medical Technology Co., Ltd., Chungdo Pharm Co., Ltd., among others.
The Point-of-Care Testing for Women Health Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness.
Key Companies in the Point-of-Care Testing for Women Health Market include
- Swiss Precision Diagnostics GmbH- Clearblue
- Wondfo
- Church & Dwight Co., Inc-First Response
- Hangzhou Singclean Medical Products Co., Ltd.
- H.P.M., Inc.
- SEKISUI Diagnostics
- INNOVITA Biological Technology Co., Ltd.
- Yangzhou VIOMED
- Cofoe Medical Technology Co., Ltd.
- Chungdo Pharm Co., Ltd.
Point-of-Care Testing for Women Health Market Industry Developments
August 2023 Clearblue introduces the first at-home product to indicate a woman’s menopause stage. The Clearblue Menopause Stage Indicator combines urine FSH measurements with age and cycle history to determine her likely menopause stage.
August 2020 Swiss Precision Diagnostics (SPD) has adopted Matrix Gemini LIMS to enhance the management of pregnancy studies. The system streamlines volunteer sample collection, laboratory testing, and clinical biobank operations, making data more accessible and processes more efficient.
Point-of-Care Testing for Women Health Market Segmentation
Point-of-Care Testing for Women Health by Product Outlook
- Instruments/Devices
- Reagents & Kits
- Consumables
Point-of-Care Testing for Women Health by Age Outlook
- Adolescent
- Adult
- Geriatric
Point-of-Care Testing for Women Health by Sample Type Outlook
- Serum
- Plasma
- Whole Blood
- Urine
- Others
Point-of-Care Testing for Women Health by Test Type Outlook
- Testosterone Test
- Estradiol Test
- Anti-Müllerian Hormone Test
- Prolactin Test
- Progesterone Test
- Follicle-stimulating Hormone Test
- Luteinizing Hormone Test
- β-hCG Test
- Others
Point-of-Care Testing for Women Health by Technology Outlook
- Colloidal Gold Lateral Flow Assays
- Fluorescence Immunoassays
- Lab-on-a-Chip
- Others
Point-of-Care Testing for Women Health by Application Outlook
- Gestational Diabetes
- Vaginal Infection
- Urinary Tract Infection
- Cervical Cancer or Pre-cancerous Conditions
- Hemoglobin Deficiency
- Breast Cancer
- Thyroid Disease
- Sexually Transmitted Infections
- Chlamydia
- Gonorrhea
- HIV
- Syphilis
- Others
- Fertility Conditions
- Polycystic Ovary Syndrome
- Ovulation Disorders
- Others
- Pregnancy Testing
- Others
Point-of-Care Testing for Women Health by Distribution Channel Outlook
- Offline
- Hospital Pharmacies
- Retail Pharmacies
- Hypermarket/Supermarket
- Online
- E-commerce Platforms
- Online Pharmacies
Point-of-Care Testing for Women Health by End-User Outlook
- Hospitals
- Diagnostic Laboratories
- Home Settings
- Others
Point-of-Care Testing for Women Health Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Southeast Asia
- Malaysia
- Singapore
- Thailand
- Vietnam
- Philippines
- Indonesia
- Rest of Southeast Asia
- Rest of Asia-Pacific
- Rest of the world
- Middle East & Africa
- South America
- Brazil
- Argentina
- Chile
- Rest of South America
| Report Attribute/Metric |
Details |
| Market Size 2024 |
USD 17.69 Billion |
| Market Size 2025 |
USD 18.83 Billion |
| Market Size 2035 |
USD 33.74 Billion |
| Compound Annual Growth Rate (CAGR) |
6.26 % (2025-2035) |
| Base Year |
2024 |
| Forecast Period |
2025-2035 |
| Historical Data |
2019-2023 |
| Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
By Product, By Age, By Sample Type, By Test Type, By Technology, By Application, By Distribution Channel, By End-User |
| Geographies Covered |
North America, Europe, Asia Pacific, Rest of the World |
| Countries Covered |
The US, Canada, Mexico, Germany, France, the UK, Italy, Spain, China, India, Japan, Australia, South Korea, Southeast Asia, Malaysia, Singapore, Thailand, Vietnam, Philippines, Indonesia, Middle East & Africa, South America, Brazil, Argentina, Chile |
| Key Companies Profiled |
Swiss Precision Diagnostics GmbH- Clearblue, Wondfo, Church & Dwight Co., Inc.-First Response, Hangzhou Singclean Medical Products Co., Ltd., W.H.P.M., Inc., SEKISUI Diagnostics, INNOVITA Biological Technology Co., Ltd., Yangzhou VIOMED, Cofoe Medical Technology Co., Ltd., Chungdo Pharm Co., Ltd. |
| Key Market Opportunities |
ยทย ย ย ย ย ย ย ย Rising awareness and health initiatives ยทย ย ย ย ย ย ย ย High cost of diagnostic imaging systems and procedures |
| Key Market Dynamics |
ยทย ย ย ย ย ย ย ย High prevalence of infectious diseases in women ยทย ย ย ย ย ย ย ย Increasing cases of infertility among women ยทย ย ย ย ย ย ย ย Growing strategic initiatives associated with the point-of-care testing for women health |
Frequently Asked Questions (FAQ) :
USD 17.69 Billion is the Point-of-Care Testing for Women Health Market in 2024
The β-hCG Test segment by Test Type holds the largest market share and grows at a CAGR of 8.32 % during the forecast period.
North America holds the largest market share in the Point-of-Care Testing for Women Health Market.
Swiss Precision Diagnostics GmbH- Clearblue, Wondfo, Church & Dwight Co., Inc.-First Response, Hangzhou Singclean Medical Products Co., Ltd., W.H.P.M., Inc., SEKISUI Diagnostics, INNOVITA Biological Technology Co., Ltd., Yangzhou VIOMED, Cofoe Medical Technology Co., Ltd., Chungdo Pharm Co., Ltd., are prominent players in the Point-of-Care Testing for Women Health Market.
The Pregnancy Testing segment dominated the market in 2024.
